NCT04855305

Brief Summary

The purpose of this multi-centered, NIH-sponsored study is to to develop an optimal protocol for using noninvasive 129Xe gas exchange MRI to detect changing disease activity in interstitial lung diseases (ILDs).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
46

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Nov 2021

Typical duration for phase_2

Geographic Reach
1 country

4 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 19, 2021

Completed
3 days until next milestone

First Posted

Study publicly available on registry

April 22, 2021

Completed
7 months until next milestone

Study Start

First participant enrolled

November 12, 2021

Completed
3.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 11, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 11, 2025

Completed
Last Updated

February 4, 2026

Status Verified

February 1, 2026

Enrollment Period

3.6 years

First QC Date

April 19, 2021

Last Update Submit

February 2, 2026

Conditions

Outcome Measures

Primary Outcomes (5)

  • Thoracic cavity volume measured in liters.

    4 years

  • RBC/barrier signal ratio (unitless).

    4 years

  • Coefficient of repeatability of RBC/barrier signal ratio (unitless).

    4 years

  • Echo time to separate RBC and barrier signals by 90 degrees (ms).

    4 years

  • Population-wide RBC/barrier signal ratio (unitless).

    4 years

Study Arms (2)

Patients with Interstitial Lung Disease

ACTIVE COMPARATOR
Drug: Hyperpolarized 129Xe

Healthy Volunteers

ACTIVE COMPARATOR
Drug: Hyperpolarized 129Xe

Interventions

Hyperpolarized 129Xe will be administered in multiple doses in volumes that are tailored to the participant's total lung capacity (TLC) followed by a breath hold of up to 15 seconds.

Healthy VolunteersPatients with Interstitial Lung Disease

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may not qualify if:

  • Outpatients of either gender, age greater than or equal to 18 years
  • Willing and able to give informed consent and adhere to visit/protocol schedules (Consent must be given before any study procedures are performed.)
  • Subject has no diagnosed pulmonary conditions
  • Subject has not smoked in the previous 5 years
  • Smoking history, if any, is less than or equal to 5 pack-years
  • No history of using other inhaled products more than 1 time per week for \> 1 year
  • Subject is less than 18 years old
  • MRI is contraindicated based on responses to MRI screening questionnaire
  • Subject is pregnant or lactating
  • Resting oxygen saturation on room air \<90%
  • Respiratory illness of a bacterial or viral etiology within 30 days of MRI
  • Subject has history of any known ventricular cardiac arrhythmia
  • Subject has history of cardiac arrest within the last year
  • Subject does not fit into Xe vest coil used for MRI 129
  • Subject cannot hold his/her breath for 15 seconds
  • +16 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

University of Iowa

Iowa City, Iowa, 52242, United States

Location

Duke University Medical Center

Durham, North Carolina, 27710, United States

Location

University of Cincinnati

Cincinnati, Ohio, 45219, United States

Location

Cincinnati Children's Hospital Medical Center

Cincinnati, Ohio, 45229, United States

Location

MeSH Terms

Conditions

Lung Diseases, Interstitial

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract Diseases

Study Officials

  • Joseph Mammarappallil, MD

    Duke University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Professor of Radiology

Study Record Dates

First Submitted

April 19, 2021

First Posted

April 22, 2021

Study Start

November 12, 2021

Primary Completion

June 11, 2025

Study Completion

June 11, 2025

Last Updated

February 4, 2026

Record last verified: 2026-02

Data Sharing

IPD Sharing
Will share

A major focus of this work is sharing and dissemination of the image acquisition and analysis methods we develop as well as standard operating procedures for 129Xe MRI.

Shared Documents
STUDY PROTOCOL, SAP, ICF, CSR, ANALYTIC CODE
Time Frame
A major focus of this work is sharing and dissemination of the image acquisition and analysis methods we develop as well as standard operating procedures for 129Xe MRI. In all instances we will adhere to the NIH Sharing Policies and Related Guidance on NIH-Funded Research Resources for Recipients of NIH Grants and Contracts on Obtaining (https://grants.nih.gov/policy/sharing.htm) and Disseminating Biomedical Research Re-sources (issued December 1999). However, we intend to greatly exceed these requirements, making as much of our work freely available to the broader research community either before, or immediately after publication of manuscripts, as well as through PubMedCentral. While we we will provide relevant protocols upon request at any time, we further intend to pursue several proactive data sharing mechanisms.
Access Criteria
We are committed to making de-identified datasets and image analysis available to to qualified investigators. When required scientifically, data including identifiers will be shared under an agreement that provides for: (1) a commitment to using data only for research purposes and not to identify any individual participant; (2) a commitment to securing the data appropriately; and (3) a commitment to destroying or returning the data after analyses are completed.

Locations